Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s | Zendy

Theodoros Kelesidis | Zendy; Thuy Tien T. Tran | Zendy; James H. Stein | Zendy; Todd T. Brown | Zendy; Carlee Moser | Zendy; Heather J. Ribaudo | Zendy; Michael P. Dubé | Zendy; Robert L. Murphy | Zendy; Otto O. Yang | Zendy; Judith S. Currier | Zendy; Grace A. McComsey | Zendy

Open Access

Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

Author(s) -

Theodoros Kelesidis,

Thuy Tien T. Tran,

James H. Stein,

Todd T. Brown,

Carlee Moser,

Heather J. Ribaudo,

Michael P. Dubé,

Robert L. Murphy,

Otto O. Yang,

Judith S. Currier,

Grace A. McComsey

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ327

Subject(s) - raltegravir , ritonavir , darunavir , atazanavir , medicine , immunology , cd14 , inflammation , gastroenterology , pharmacology , viral load , immune system , human immunodeficiency virus (hiv) , antiretroviral therapy

It is unclear whether the integrase inhibitor raltegravir (RAL) reduces inflammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research